Not A Member?       Forget Password?
          Click HERE                   Click HERE
   and Register FREE
Fibrocell Science, Inc.
( :FCSC ) / David Pernock
diaDexus, Inc.
( OTCBB:DDXS ) / Dr. Brian Ward
NovaBay Pharmaceuticals, Inc.
( NYSE:NBY ) / Ron Najafi, Ph.D. Thomas Paulson, M.B.A.
EnerJex Resources, Inc.
( OTCBB:ENRJ ) / Robert Watson, Jr. Atticus Lowe
League Now Holdings Corporation (Infiniti Systems Group, Inc.)
( OTCBB:LNWZ ) / Mr. John L. Bianco Mr. D. Bruce Veness
Sunshine Biopharma, inc.
( OTCBB:SBFM ) / Steve N. Slilaty Camille Sebaaly
TheraBiogen, Inc.
( OTCBB:TRAB ) / Kelly Hickel
Trimedyne, Inc.
( OTCBB:TMED ) / Marvin P. Loeb
XsunX Inc.
( OTCBB:XSNX ) / Mr. Tom M. Djokovich
October 5, 2015 CEOcast Weekly Newsletter
Companies featured in this edition of the newsletter: IMNP, ZIVO The stock market ended the week the week on an upbeat note despite stumbling at the start. The weak nonfarm payroll report caused t... Click here for more...

Enzo Biochem, Inc.
Enzo Biochem, Inc. is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques. Enzo is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological processes to develop research tools, diagnostics and therapeutics and serves as a provider of test services, including esoteric tests, to the medical community.
Immune Pharmaceuticals, Inc.

Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops and commercializes targeted therapeutics for the treatment of inflammatory diseases and cancer. The company's lead product candidate is Bertilimumab, a human monoclonal antibody, which is under Phase II clinical trial for the treatment of ulcerative colitis, bullous pemphigoid, and Crohn's disease. It is also developing AmiKet, a prescription topical analgesic cream, which is in Phase III clinical trial to treat peripheral neuropathies; NanomAbs technology platform, an antibody-drug conjugate platform for the treatment of cancer; and Crolibulin, a novel small molecule vascular disruption agent and apoptosis inducer, which is under Phase I/II clinical trials for the treatment of patients with solid tumors. The company has license, and other collaborative research and development arrangements with iCo Therapeutics Inc.; Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.; MabLife SAS; Lonza Sales AG; Dalhousie University; Shire Biochem, Inc.; and Endo Pharmaceuticals. The company was founded in 2010 and is headquartered in New York, New York.


Copyright © 2001-2015. All Rights Reserved. Disclaimer | Privacy Policy